Athos Service and MIG Capital led a $69m Series B funding round in iOmx Therapeutics, a cancer immunotherapy treatments developer, with participation from Wellington Partners, Sofinnova Partners and M Ventures. "In the vital world of cancer immunotherapy, iOmx's platform technology stands out because it screens for novel druggable immune checkpoint targets on tumor cells instead of T cells, thereby allowing the development of drugs that can prevent tumor immune evasion." He added: "We are pleased to join a world-class investor consortium and to begin to work with a highly talented and dedicated team at iOmx," Matthias Kromayer, MIG Capital Managing Partner.